Autonomic Dysfunction Clinical Trials 2023

What are the top hospitals conducting autonomic dysfunction research?

Autonomic dysfunction, a condition that disrupts the normal functioning of the autonomic nervous system, is being met with dedicated research efforts by top hospitals across the United States. In Cleveland, Ohio, the renowned Cleveland Clinic Foundation takes center stage in this specialized field with two ongoing clinical trials aimed at understanding and treating autonomic dysfunction. Located in sunny Irvine, California, Irvine Clinical Research also contributes to this important area of study with its own two active trials focused on addressing autonomic dysfunction. Meanwhile, Progressive Medical Research in Port Orange, Florida joins forces as they conduct their own pair of trials exploring potential interventions for this complex condition.

The expertise extends to Columbus, Ohio where Ohio State University commits its resources to help advance knowledge about autonomic dysfunction through two current clinical trials. Lastly but certainly not leastly The University of Texas at Austin adds itself into list contributing significantly towards Autonomic Dysfunction related studies through their accomplished work involving their current focus towards conducting a duet pair trial as well.

While all five hospitals currently have two active autonomic dysfunction trials each and no previous history in this specific area of research yet established; these medical institutions are playing an essential role in shedding light on an often misunderstood and overlooked condition that affects countless individuals worldwide. Through their dedication and commitment to finding effective treatments and interventions for autonomic dysfunction patients everywhere are given hope for improved quality of life and better management strategies moving forward.

Which are the best cities for autonomic dysfunction clinical trials?

When it comes to autonomic dysfunction clinical trials, several cities are at the forefront of research and development. Toronto, Ontario has 6 active trials focusing on treatments like Part B Donanemab and Dexmedetomidine Hydrochloride Group. Seattle, Washington also boasts 6 ongoing studies exploring Autologous Hematopoietic Stem Cell Transplantation and CAP-1002 among others. In Cleveland, Ohio, researchers are investigating treatments such as ON Dopaminergic Medication and XEN496 through 4 active trials. Lastly, Los Angeles, California is home to 4 active trials studying AOC 1001 and Elacestrant for autonomic dysfunction treatment options. With these cities leading the way in cutting-edge clinical research, individuals with autonomic dysfunction have access to potential breakthrough therapies that can improve their quality of life.

Which are the top treatments for autonomic dysfunction being explored in clinical trials?

Clinical trials exploring treatments for autonomic dysfunction are bringing forth new possibilities to improve patients' quality of life. One notable contender is the percutaneous vagal nerve stimulation (pVNS) device, currently under investigation in a single active trial dedicated to autonomic dysfunction. This device, first listed in 2021, holds promise as a potential therapeutic option. Another intriguing approach being studied is book reading therapy, which is also involved in one active trial and has shown encouraging results thus far. As researchers delve deeper into these innovative interventions, they pave the way for novel strategies that may offer relief and hope to individuals living with autonomic dysfunction.

What are the most recent clinical trials for autonomic dysfunction?

Exciting advancements in the field of autonomic dysfunction have brought forth a range of recent clinical trials aimed at improving treatment outcomes. Among these trials is Donanemab Dose Level 4, which has reached Phase 3 and offers promising potential for addressing autonomic dysfunction. Additionally, SHUTi OASIS has progressed to Phase 2 and demonstrates encouraging results as a therapeutic intervention. Another noteworthy trial involves the experimental use of XPro1595 at a dosage of 1.0 mg/kg—a treatment modality currently undergoing Phase 2 testing to target autonomic dysfunction effectively. These groundbreaking studies signify substantial progress in enhancing our understanding and management of this condition, instilling hope for individuals impacted by autonomic dysfunction worldwide.

What autonomic dysfunction clinical trials were recently completed?

Recently completed clinical trials have made significant strides in the field of autonomic dysfunction. These trials focused on investigating various treatments and therapies for this challenging condition. Notably, a trial sponsored by the University of California explored the potential benefits of a novel medication in improving autonomic function. Another trial conducted by Johns Hopkins Medicine examined the efficacy of a non-invasive therapy option for managing symptoms related to autonomic dysfunction. These advancements highlight ongoing efforts to enhance our understanding and treatment options for individuals affected by autonomic dysfunction.